A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects with Ovarian Cancer.

Completed

Conditions: Malignant neoplasm of unspecifiedovary,

Registration Number: CTRI/2018/07/014835

Lead Sponsor: Ayana Pharma Ltd

Brief Summary: This study is a randomized, open label, two arm, single dose, crossover bioequivalence study. Study drug administration will be conducted on the days when the subjects are scheduled to receive their usual therapy so that treatment regimen is not altered. This study will be conducted in female subjects aged 18 to 65 years diagnosed with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy and who are already receiving or scheduled to start therapy with Doxorubicin Hydrochloride Liposome Injection product. Doxorubicin hydrochloride liposome injection consists of doxorubicin hydrochloride, encapsulated in pegylated liposomes for intravenous administration. This study has an adaptive 2-stage design. A sufficient number of subjects with ovarian cancer shall be recruited to have approximately 42 evaluable subjects completing all follow up procedures. The expected duration of study participation for each subject is approximately 42 days from day of enrollment (day of dosing). An interim analysis of free and encapsulated doxorubicin will be performed at the end of Stage 1. If the bioequivalence of encapsulated and free doxorubicin has been established, then the study will be stopped. Otherwise, the study may continue into Stage 2 with additional number of ovarian cancer subjects. A final evaluation of bioequivalence based on free and encapsulated doxorubicin will be performed at the end of Stage 2 and will include all enrolled subjects completing the study.

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Female

Target Recruitment: 42

Inclusion Criteria

Adult female subjects between 18 to 65 years of age (both inclusive) at the time of screening visit.
Subjects with histologically or cytological proven ovarian cancer, whose disease has progressed or recurred after platinum-based chemotherapy and scheduled to start therapy with or who are already receiving an approved dose of 50 mg per meter square Doxorubicin Hydrochloride Liposome Injection product.
Subjects expected to be able to receive both doses of Doxorubicin Hydrochloride Liposome Injection.
Subjects eligible for receiving a dose of 50 mg per meter square of Doxorubicin Hydrochloride Liposome Injection.
Subjects with Performance less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) performance scale 6.
Cardiac function (LVEF) greater than or equal to 50 percentage.
Adequate renal, hepatic and bone marrow function without blood product or hematopoietic growth factor support.
Subjects able to understand the investigational nature of this study.
Availability of subject for the entire study period and willingness to adhere to protocol requirements.
For subjects of child-bearing potential, serum beta HCG pregnancy test at screening and urine pregnancy test prior to dosing must be negative and subjects agree to use an acceptable and effective approved method of contraception 11.
Subjects of non-childbearing potential who are either surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or greater than 1 year postmenopausal with follicle stimulating hormone in the postmenopausal range 12.
Signed written informed consent.

Exclusion Criteria

Subjects with history or presence of significant: o Allergy or significant history of hypersensitivity or idiosyncratic reactions to a conventional formulation of Doxorubicin Hydrochloride and/or any components of Doxorubicin Hydrochloride liposome injection.
o Clinically significant pulmonary, hepatic, renal, bone marrow, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
o Impaired cardiac function 2.
Alcohol dependence, alcohol abuse or drug abuse or addiction with any recreational drug within the past one year.
Active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, p.
carinii or other microorganism (bacterial, viral or fungal).
Clinically significant illness (except ovarian cancer) within four weeks prior to dosing.
Prior radiation therapy to mediastinum 6.
Concomitant use of other cytotoxic or cytostatic drugs or of radiotherapy within four weeks prior to dosing 7.
Subject under treatment of myelotoxic drugs, other than doxorubicin (liposomal).
Use of prescription or non-prescription herbal and dietary supplements, within 7 days prior to dosing.
Subjects with other known active malignancies requiring treatment within 3 years (except for ovarian and/or skin cancer).
Subjects with known brain metastasis and/or subjects considered for radiotherapy treatment.
Positive result to any of the following: HIV-1/2, hepatitis A, B and C; syphilis.
Subjects who have: o Systolic blood pressure less than 90 mmHg or more than 160 mmHg o Diastolic blood pressure less than 60 mmHg or more than 95 mmHg o Pulse rate below 55 per min.
or above 100 per min 14.
Subjects with abnormal laboratory parameters 15.
Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending other investigational device or drug trial(s).
Subjects who are legally detained in an official institute.
Subjects with prior doxorubicin exposure that would result in a total lifetime exposure of 550 mg per meter square or more after four cycles of treatment.
Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or that could prevent, limit, or confound the protocol-specified assessments 19.
Females of childbearing potential unwilling to use acceptable contraception (as identified in the protocol) throughout the trial and for 6 months after the last dose of study drug.
Pregnant or breast-feeding subjects.

Study & Design

Study Type: BA/BE

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assessment of the bioequivalence and the safety of LC-101 (TEST Product) in comparison to the US Reference standard (REFERENCE product) in subjects with ovarian	Throughout 14 days after both dosing.
cancer.	Throughout 14 days after both dosing.

Secondary Outcome Measures

Name	Time	Method
NA	NA

Trial Locations

Locations (18): Aman Hospital and Research Center
🇮🇳
Vadodara, GUJARAT, India
Apex Wellnesss Rishikesh Hospital
🇮🇳
Nashik, MAHARASHTRA, India
Dr B Borooah Cancer Institute
🇮🇳
Kamrup, ASSAM, India
HCG City Cancer Centre
🇮🇳
Krishna, ANDHRA PRADESH, India
HCG Manavata Cancer Centre
🇮🇳
Nashik, MAHARASHTRA, India
K R Hospital
🇮🇳
Mysore, KARNATAKA, India
Kailash Cancer Hospital And Research Center
🇮🇳
Vadodara, GUJARAT, India
Mahatma Gandhi Cancer Hospital & Research Institute
🇮🇳
Visakhapatnam, ANDHRA PRADESH, India
Mahatma Gandhi Mission -Medical College & Hospital
🇮🇳
Aurangabad, MAHARASHTRA, India
MNJ Institute of Oncology& Regional Cancer Center
🇮🇳
Hyderabad, ANDHRA PRADESH, India
Scroll for more (8 remaining)
Aman Hospital and Research Center
🇮🇳Vadodara, GUJARAT, India
Dr Jigar Patel
Principal investigator
09879794049
jigarpatel5785@gmail.com